Dutasteride
Brand names: Avodart, Dutasteride
At a glance
- Medicare prescriptions, 2024
- 666,765
- Medicare drug cost
- $22.1M
- Average cost per prescription
- $33.09
- Clinicians who prescribed it
- 19,625
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Dutasteride is a 5 alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for BPH-related surgery.
From the FDA-approved prescribing information (label dated August 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Urology 40.9%
- Internal Medicine 17.6%
- Family Medicine 17.3%
- Nurse Practitioners 8.1%
- Physician Assistants 6.8%
- Dermatology 4.4%
- General Practice 1.0%
- Geriatric Medicine 0.9%
- Nephrology (Kidney) 0.7%
- Cardiology 0.4%
- Hospitalist 0.1%
- Pulmonology 0.1%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 11% from 2019 to 2024.
Biggest change by state since 2019
- Washington +35%
- Kansas +31%
- Wisconsin +30%
- Florida +30%
- Texas +27%
- New York (smallest change) −7%
- West Virginia (smallest change) −5%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Avkare
| Strength | Looks like | Imprint |
|---|---|---|
| 0.5 mg | yellow capsule, 18 mm | A 75 |
Humanwell Puracap Pharmaceutical (wuhan), Ltd.
| Strength | Looks like | Imprint |
|---|---|---|
| 0.5 mg | yellow capsule, 19 mm | PC23 |
Strides Pharma Science Limited
| Strength | Looks like | Imprint |
|---|---|---|
| 0.5 mg | yellow capsule, 19 mm | 05 |
Waylis Therapeutics LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 0.5 mg | yellow oval capsule, 19 mm | GX CE2 |
Zydus Pharmaceuticals USA Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 0.5 mg / 0.4 mg tamsulosin hydrochloride | white capsule, 23 mm | 640 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.